Manhattan, NY- March 29, 2014 – (Techsonian) – ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced recently that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, presented at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel in New York City.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended lower -6.39% and complete the day at $4.69. The total number of shares changed hands during the day was 1.66 million. After opening at $5.00, the stock hit as high as $5.09. However, it traded between $1.49 and $5.58 over the last twelve months.
Has ZIOP Found The Bottom and Ready To Move Up? Find Out Here
UQM Technologies Inc (NYSEMKT:UQM) declared that it has reached a significant milestone with the official registration for the ISO/TS 16949:2009 Quality Standard. This registration is considered the highest level of quality standards for the automotive industry and encompasses UQM’s entire operation including the design, manufacturing and service of the company’s distinctive product offerings.
UQM Technologies Inc (NYSEMKT:UQM) closed yesterday at $2.52, a -3.82% decrease. Around 1.66 million shares were exchanged during the last trade, while the average volume is about 1.24 million shares. The company is now valued at around $94.59 million.
Has UQM Found The Bottom And Ready To Gain Momentum? Find Out Here
NovaGold Resources Inc. (USA)(NYSEMKT:NG) explores and increases mineral properties in the United States, Canada, and worldwide. The company primarily explores for gold, silver, and copper deposits. Its flagship projects include the Donlin Gold project that is located in southwestern Alaska covering an area of about 81,361 acres; and the Galore Creek project that is located in northwestern British Columbia, which covers approximately an area of 293,837 acres.
NovaGold Resources Inc. (USA) (NYSEMKT:NG) moved 3.31 percent higher at $3.75 and traded between $3.58 and $3.78 after opening the day at $3.58. Its performance over the last five days remained -6.72%, which stands at 1.63% for a month. Going back further than one month, 1-year performance after recent close was 53.69%.
For How Long NG Gloss will Attract Investors? Find out via this report
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the quarter and year ended December 31, 2013. For the year ended December 31, 2013, the Company incurred a net loss of $8.8 million, or $0.16 per basic and diluted share, compared to a net loss of $14.5 million for the year ended December 31, 2012, or $0.35 per basic and diluted share.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares fall, losing -4.03 percent to close at $1.19. The stock is around 21.43% this year and -56.57% for the last 12 months. The stock traded on a volume of 1.55 million shares and the average volume of the stock remained 1.74 million shares.
Will IMUC Get Buyers Even After The Recent Rally? Find Out Here